|
SG11201504410PA
(en)
|
2012-12-07 |
2015-07-30 |
Chemocentryx Inc |
Diazole lactams
|
|
KR20160081898A
(ko)
|
2013-09-06 |
2016-07-08 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
|
|
HUE038169T2
(hu)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazol származékok mint immunomodulátorok
|
|
BR112017019306A2
(pt)
*
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
|
|
MY196130A
(en)
|
2015-03-10 |
2023-03-16 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
|
|
CN107427497A
(zh)
*
|
2015-03-10 |
2017-12-01 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的3‑取代的1,3,4‑噁二唑和噻二唑化合物
|
|
RU2697665C1
(ru)
|
2015-07-27 |
2019-08-16 |
Чонг Кун Данг Фармасьютикал Корп. |
Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их
|
|
HUE048534T2
(hu)
|
2015-07-27 |
2020-07-28 |
Chong Kun Dang Pharmaceutical Corp |
1,3,4-oxadiazol-szulfamid-származékok hiszton deacetiláz 6 inhibitorként és ezt tartalmazó gyógyszerkészítmény
|
|
CN108026056B
(zh)
|
2015-07-27 |
2021-08-03 |
株式会社钟根堂 |
作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
|
|
BR112018002304B1
(pt)
|
2015-08-04 |
2023-12-19 |
Chong Kun Dang Pharmaceutical Corp |
Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
WO2017065473A1
(en)
|
2015-10-12 |
2017-04-20 |
Chong Kun Dang Pharmaceutical Corp. |
Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
|
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
HRP20221035T1
(hr)
|
2015-11-19 |
2022-11-11 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
|
PE20230731A1
(es)
|
2015-12-22 |
2023-05-03 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
|
EP3402503B1
(en)
|
2016-01-13 |
2020-10-21 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
|
EP3439653B1
(en)
|
2016-04-07 |
2021-01-20 |
ChemoCentryx, Inc. |
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
TWI771305B
(zh)
|
2016-06-20 |
2022-07-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
|
EP3474845B1
(en)
|
2016-06-27 |
2024-03-20 |
ChemoCentryx, Inc. |
Immunomodulator compounds
|
|
AU2017294231B2
(en)
|
2016-07-05 |
2021-09-09 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd |
Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
|
|
WO2018013789A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US20180057486A1
(en)
|
2016-08-29 |
2018-03-01 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018047139A1
(en)
*
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Compounds as modulators of tigit signalling pathway
|
|
WO2018047143A1
(en)
*
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
|
WO2018051255A1
(en)
*
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
WO2018055080A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
|
|
CR20190181A
(es)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
WO2018119266A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
PE20200005A1
(es)
|
2016-12-22 |
2020-01-06 |
Incyte Corp |
Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
|
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3565560B1
(en)
|
2017-01-09 |
2024-05-29 |
OnkosXcel Therapeutics, LLC |
Predictive and diagnostic methods for prostate cancer
|
|
CN108395443B
(zh)
*
|
2017-02-04 |
2021-05-04 |
广州丹康医药生物有限公司 |
抑制程序性死亡受体配体1的环状化合物及其用途
|
|
TW201841896A
(zh)
*
|
2017-04-26 |
2018-12-01 |
大陸商南京聖和藥業股份有限公司 |
作為pd—l1抑制劑的雜環類化合物
|
|
CN108863963B
(zh)
*
|
2017-05-08 |
2022-05-27 |
南京圣和药物研发有限公司 |
作为pd-l1抑制剂的杂环类化合物
|
|
CN109096219B
(zh)
*
|
2017-06-20 |
2023-03-21 |
广州丹康医药生物有限公司 |
一种新型抗pd-l1化合物、其应用及含其的组合物
|
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
|
IL272258B
(en)
|
2017-07-28 |
2022-08-01 |
Chemocentryx Inc |
Immunomodulator compounds
|
|
US10392405B2
(en)
|
2017-08-08 |
2019-08-27 |
Chemocentryx, Inc. |
Macrocyclic immunomodulators
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
CA3078872A1
(en)
|
2017-10-11 |
2019-04-18 |
Aurigene Discovery Technologies Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
CN109678796B
(zh)
*
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
|
WO2019084463A1
(en)
*
|
2017-10-26 |
2019-05-02 |
Southern Research Institute |
OXADIAZOLES AND THIADIAZOLES AS INHIBITORS OF TGF-BETA
|
|
SG11202003625VA
(en)
|
2017-11-03 |
2020-05-28 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
JP7378395B2
(ja)
|
2017-11-06 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
免疫調節のためのコンジョイントセラピー
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3712178A4
(en)
|
2017-11-14 |
2021-08-11 |
Green Cross Lab Cell Corporation |
ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
SG11202005962YA
(en)
|
2017-12-29 |
2020-07-29 |
Guangzhou Maxinovel Pharmaceuticals Co Ltd |
Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
|
|
CN112004537A
(zh)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
|
|
US10568874B2
(en)
|
2018-02-22 |
2020-02-25 |
Chemocentryx, Inc. |
Indane-amines as PD-L1 antagonists
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
CA3093742A1
(en)
|
2018-03-12 |
2019-09-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
FI3774791T3
(fi)
|
2018-03-30 |
2023-03-21 |
Incyte Corp |
Heterosyklisiä yhdisteitä immunomodulaattoreina
|
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
BR112020022936A2
(pt)
|
2018-05-11 |
2021-02-02 |
Incyte Corporation |
derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
|
KR102316234B1
(ko)
|
2018-07-26 |
2021-10-22 |
주식회사 종근당 |
히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
WO2020061429A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
CN111057069B
(zh)
*
|
2018-10-16 |
2024-01-26 |
武汉光谷通用名药物研究院有限公司 |
一种环状化合物、其应用及组合物
|
|
CN111100086B
(zh)
*
|
2018-10-25 |
2022-07-01 |
南京圣和药业股份有限公司 |
1,3,4-噁二唑-2-环丁基类化合物及其制备方法
|
|
WO2020083336A1
(zh)
*
|
2018-10-25 |
2020-04-30 |
南京圣和药业股份有限公司 |
1,3,4-噁二唑-2-环丁基类化合物及其制备方法和应用
|
|
EP3873903B1
(en)
|
2018-10-31 |
2024-01-24 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
US11071730B2
(en)
|
2018-10-31 |
2021-07-27 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
KR20210089195A
(ko)
|
2018-11-02 |
2021-07-15 |
상하이 맥시노벨 파마수티컬스 씨오., 엘티디. |
비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도
|
|
ES2971964T3
(es)
|
2018-11-28 |
2024-06-10 |
Inst Nat Sante Rech Med |
Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
|
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
WO2020127059A1
(en)
|
2018-12-17 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
US20220073626A1
(en)
|
2019-01-03 |
2022-03-10 |
Institut National De La Santé Et De La Recheche Médicale (Inserm) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
KR20210116525A
(ko)
|
2019-01-14 |
2021-09-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
|
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
CN113543851A
(zh)
|
2019-03-07 |
2021-10-22 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
KR20210137518A
(ko)
|
2019-03-07 |
2021-11-17 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
CN109824621A
(zh)
*
|
2019-03-28 |
2019-05-31 |
中国药科大学 |
噁二唑类和噻二唑类化合物及其制备方法和用途
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
|
AU2020276277A1
(en)
|
2019-05-15 |
2021-12-09 |
Chemocentryx, Inc. |
Triaryl compounds for treatment of PD-L1 diseases
|
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
CA3143104A1
(en)
|
2019-06-12 |
2020-12-17 |
Technical University Of Denmark |
Dissacharide formulations for controlled drug release
|
|
KR20220024701A
(ko)
|
2019-06-20 |
2022-03-03 |
케모센트릭스, 인크. |
Pd-l1 질환의 치료를 위한 화합물
|
|
BR112021025888A2
(pt)
|
2019-07-10 |
2022-04-26 |
Chemocentryx Inc |
Indanos como inibidores de pd-l1
|
|
WO2021030162A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
MX2022003658A
(es)
|
2019-09-30 |
2022-04-25 |
Gilead Sciences Inc |
Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
|
|
JP7559059B2
(ja)
|
2019-09-30 |
2024-10-01 |
インサイト・コーポレイション |
免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
MX2022004450A
(es)
|
2019-10-16 |
2022-05-03 |
Chemocentryx Inc |
Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
|
|
US11713307B2
(en)
|
2019-10-16 |
2023-08-01 |
Chemocentryx, Inc. |
Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
|
|
MX2022005651A
(es)
|
2019-11-11 |
2022-07-27 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
|
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
JP2023509155A
(ja)
|
2020-01-03 |
2023-03-07 |
上▲海▼翰森生物医▲薬▼科技有限公司 |
ビフェニル系誘導体阻害剤、その調製方法及び使用
|
|
IL294557A
(en)
|
2020-01-07 |
2022-09-01 |
Univ Texas |
Enhanced human methylthioadenosine/adenosine-depleting enzyme variants for cancer therapy
|
|
CA3164559A1
(en)
|
2020-01-31 |
2021-08-05 |
Lars Mueller |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
JP2023518433A
(ja)
|
2020-03-20 |
2023-05-01 |
ギリアード サイエンシーズ， インコーポレイテッド |
４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
|
|
CA3176356A1
(en)
|
2020-04-22 |
2021-10-28 |
Anne BROOKS |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4212511A1
(en)
|
2020-09-09 |
2023-07-19 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
EP4236960A1
(en)
|
2020-10-28 |
2023-09-06 |
Ikena Oncology, Inc. |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
|
MX2023005192A
(es)
|
2020-11-04 |
2023-05-15 |
Heidelberg Pharma Res Gmbh |
Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
KR20230117573A
(ko)
|
2020-11-06 |
2023-08-08 |
인사이트 코포레이션 |
Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
JP2023554587A
(ja)
|
2020-11-12 |
2023-12-28 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
AU2021392630A1
(en)
|
2020-12-02 |
2023-06-22 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
|
AR125130A1
(es)
|
2021-03-19 |
2023-06-14 |
Heidelberg Pharma Res Gmbh |
Conjugados de amatoxina y anticuerpo específicos de linfocitos b
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック， インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
|
TW202310852A
(zh)
|
2021-05-13 |
2023-03-16 |
美商基利科學股份有限公司 |
ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
|
|
TW202317200A
(zh)
|
2021-06-11 |
2023-05-01 |
美商基利科學股份有限公司 |
Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
|
|
TW202315637A
(zh)
|
2021-06-11 |
2023-04-16 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
BR112023026966A2
(pt)
|
2021-07-02 |
2024-03-12 |
Hoffmann La Roche |
Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
|
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
JP2024527049A
(ja)
|
2021-07-28 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
CN118765283A
(zh)
|
2021-11-17 |
2024-10-11 |
国家健康科学研究所 |
通用沙贝病毒疫苗
|
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
AU2022450448A1
(en)
|
2022-04-01 |
2024-10-10 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4282448A1
(en)
|
2022-05-23 |
2023-11-29 |
Danmarks Tekniske Universitet |
Porous expanding biocompatible scaffolds
|
|
EP4282435A1
(en)
|
2022-05-23 |
2023-11-29 |
Danmarks Tekniske Universitet |
Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|